What is the equity of 3SBio this year?
3SBio has equity of 14.03 B CNY this year.
3SBio Equity 2024
3SBio Equity
14.03 B CNY
Ticker
1530.HK
ISIN
KYG8875G1029
WKN
A14T7Q
In 2024, 3SBio's equity was 14.03 B CNY, a 8.57% increase from the 12.93 B CNY equity in the previous year.
3SBio Aktienanalyse
What does 3SBio do?
3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing 3SBio's Equity
3SBio's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding 3SBio's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating 3SBio's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
3SBio's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in 3SBio’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about 3SBio stock
What was the equity of 3SBio compared to the previous year?
The equity of 3SBio has increased/decreased by 8.57% increased compared to the previous year.
What impact does a high equity have on investors of 3SBio?
A high equity is advantageous for investors of 3SBio as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of 3SBio?
A low equity can be a risk for investors of 3SBio, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of 3SBio affect the company?
An increase in equity of 3SBio can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of 3SBio affect the company?
A reduction in equity of 3SBio can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of 3SBio?
Some factors that can affect the equity of 3SBio include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of 3SBio so important for investors?
The equity of 3SBio is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can 3SBio take to change the equity?
To change equity, 3SBio can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does 3SBio pay?
Over the past 12 months, 3SBio paid a dividend of 0.1 CNY . This corresponds to a dividend yield of about 1.69 %. For the coming 12 months, 3SBio is expected to pay a dividend of 0.11 CNY.
What is the dividend yield of 3SBio?
The current dividend yield of 3SBio is 1.69 %.
When does 3SBio pay dividends?
3SBio pays a quarterly dividend. This is distributed in the months of July, July, July, August.
How secure is the dividend of 3SBio?
3SBio paid dividends every year for the past 0 years.
What is the dividend of 3SBio?
For the upcoming 12 months, dividends amounting to 0.11 CNY are expected. This corresponds to a dividend yield of 1.87 %.
In which sector is 3SBio located?
3SBio is assigned to the 'Health' sector.
Wann musste ich die Aktien von 3SBio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of 3SBio from 8/5/2024 amounting to 0.25 CNY, you needed to have the stock in your portfolio before the ex-date on 7/22/2024.
When did 3SBio pay the last dividend?
The last dividend was paid out on 8/5/2024.
What was the dividend of 3SBio in the year 2023?
In the year 2023, 3SBio distributed 0.2 CNY as dividends.
In which currency does 3SBio pay out the dividend?
The dividends of 3SBio are distributed in CNY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von 3SBio
Our stock analysis for 3SBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 3SBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
